Intra-Cellular Therapies, Inc.
ITCINASDAQHealthcare
$131.87
+$0.00(+0.00%)
Market Cap$14.0B
P/E Ratio—
52W High$131.98
52W Low$64.09
Intra-Cellular Therapies, Inc. (ITCI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ITCI · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.68B | $0.46B | $0.25B | $0.08B | $0.02B |
| Cost of Revenue | $0.06B | $0.03B | $0.02B | $0.01B | $0.00B |
| Gross Profit | $0.62B | $0.43B | $0.23B | $0.07B | $0.02B |
| Gross Margin %(computed) | 91.63% | 92.73% | 91.79% | 90.17% | 91.59% |
| Operating Expenses | |||||
| R&D Expenses | $0.24B | $0.18B | $0.13B | $0.09B | $0.07B |
| G&A Expenses | $0.00B | $0.32B | $0.27B | $0.19B | $0.15B |
| Total Operating Expenses | $0.74B | $0.59B | $0.49B | $0.36B | $0.25B |
| Operating Income | ($0.12B) | ($0.16B) | ($0.26B) | ($0.29B) | ($0.23B) |
| Operating Margin %(computed) | -17.14% | -34.32% | -105.82% | -349.65% | — |
| Interest Income | $0.04B | $0.02B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.07B) | ($0.14B) | ($0.26B) | ($0.28B) | ($0.23B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.07B) | ($0.14B) | ($0.26B) | ($0.28B) | ($0.23B) |
| Net Margin %(computed) | -10.97% | -30.08% | -102.86% | -347.73% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.72 | $-1.46 | $-2.72 | $-3.50 | $-3.23 |
| Wtd Avg Shares | 0.10B | 0.10B | 0.09B | 0.08B | 0.07B |
| EBITDA | ($0.12B) | ($0.16B) | ($0.26B) | ($0.29B) | ($0.23B) |
| EBITDA Margin %(computed) | -17.14% | -34.21% | -105.55% | -348.99% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Intra-Cellular Therapies, Inc. data
About Intra-Cellular Therapies, Inc. (ITCI) Income Statement
Intra-Cellular Therapies, Inc. (ITCI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, ITCI reported revenue of $0.68B, gross profit of $0.62B (gross margin 91.63%), and net income of ($0.07B) — a net profit margin of -10.97%.
Frequently asked questions
ITCI · 4 questionsIntra-Cellular Therapies, Inc. (ITCI) reported revenue of $0.68B for 2024, up 46.6% year-over-year.
ITCI revenueITCI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09